Literature DB >> 28102522

Present and Future of Interventional Treatment of Resistant Hypertension.

Ayhan Yoruk1, Sinan S Tankut1, John P Gassler1, John D Bisognano2.   

Abstract

The increasing prevalence of hypertension, a significant cause of disability and premature death throughout the world, is a major public health concern. This is especially true for the subset of patients who suffer from resistant hypertension, which is associated with a fourfold greater risk of cardiovascular events as compared to those hypertensive patients able to achieve target blood pressure. Though quite daunting in number and ill effect, hypertension remains the most common and the most important modifiable risk factor for coronary heart disease, congestive heart failure, peripheral vascular disease, stroke, and chronic kidney disease. Therefore, the ongoing development of novel therapies for the management of hypertension is of utmost importance. This review evaluates the present and future of interventional treatment of resistant hypertension, most of which remains investigational and warrants critical assessment.

Entities:  

Keywords:  Hypertension; Resistant hypertension; Sympathetic Nervous System

Mesh:

Year:  2017        PMID: 28102522     DOI: 10.1007/s11906-017-0702-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  21 in total

1.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Authors:  George L Bakris; Mitra K Nadim; Hermann Haller; Eric G Lovett; Jill E Schafer; John D Bisognano
Journal:  J Am Soc Hypertens       Date:  2012-02-15

2.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Authors:  John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

3.  Baroreflex activation therapy: future use as therapy for severe or resistant hypertension?

Authors:  John D Bisognano
Journal:  J Am Soc Hypertens       Date:  2016-04-30

4.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

5.  Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.

Authors:  William T Abraham; Michael R Zile; Fred A Weaver; Christian Butter; Anique Ducharme; Marcel Halbach; Didier Klug; Eric G Lovett; Jochen Müller-Ehmsen; Jill E Schafer; Michele Senni; Vijay Swarup; Rolf Wachter; William C Little
Journal:  JACC Heart Fail       Date:  2015-05-14       Impact factor: 12.035

6.  Reversal of reflex-induced myocardial ischemia by median nerve stimulation: a feline model of electroacupuncture.

Authors:  P Li; K F Pitsillides; S V Rendig; H L Pan; J C Longhurst
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

7.  Long-Lasting Reduction of Blood Pressure by Electroacupuncture in Patients with Hypertension: Randomized Controlled Trial.

Authors:  Peng Li; Stephanie C Tjen-A-Looi; Ling Cheng; Dongmei Liu; Jeannette Painovich; Sivarama Vinjamury; John C Longhurst
Journal:  Med Acupunct       Date:  2015-08-01

8.  Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study.

Authors:  Edoardo Gronda; Gino Seravalle; Gianmaria Brambilla; Giuseppe Costantino; Andrea Casini; Ali Alsheraei; Eric G Lovett; Giuseppe Mancia; Guido Grassi
Journal:  Eur J Heart Fail       Date:  2014-07-28       Impact factor: 15.534

Review 9.  Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation.

Authors:  Vikas Kapil; Paul A Sobotka; Manish Saxena; Anthony Mathur; Charles Knight; Eamon Dolan; Alice Stanton; Melvin D Lobo
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

10.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.

Authors:  Maciej Tomaszewski; Christobelle White; Prashanth Patel; Nicholas Masca; Ravi Damani; Joanne Hepworth; Nilesh J Samani; Pankaj Gupta; Webster Madira; Adrian Stanley; Bryan Williams
Journal:  Heart       Date:  2014-04-02       Impact factor: 5.994

View more
  2 in total

1.  Association between osteosarcopenic obesity and hypertension among four minority populations in China: a cross-sectional study.

Authors:  Xingcai Chen; Cunqing Kong; Hongrong Yu; Jiangu Gong; Ling Lan; Lining Zhou; Jichun Gong; Peng Liu; Lin Xu; Qiongying Deng
Journal:  BMJ Open       Date:  2019-07-18       Impact factor: 2.692

2.  Musical auditory stimulus acutely influences heart rate dynamic responses to medication in subjects with well-controlled hypertension.

Authors:  Eli Carlos Martiniano; Milana Drumond Ramos Santana; Érico Luiz Damasceno Barros; Maria do Socorro da Silva; David Matthew Garner; Luiz Carlos de Abreu; Vitor E Valenti
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.